Thromboprophylaxis in Patients With COVID-19
SurgeryPage Navigation
BACKGROUND
Hospitalized patients of COVID-19 are often observed to have biomarkers of hypercoagulable state with an increased chance of incidence of VTE. In response to this, CHEST issued a rapid clinical guidance for prevention of VTE by incorporating the improved evidence updated in the past 18 months.
STUDY DESIGN AND METHODS
The research focused on the question of finding the optimal approach to thromboprophylaxis in hospitalized patients. To obtain the answers MEDLINE is searched and eight randomized controlled trials and one observational study were included in the study and a meta-analysis was performed. The panel created summaries using the GRADE Evidence-to-Decision framework. Updated guidance statements were drafted, and a modified Delphi approach was used for obtaining consensus.
RESULTS
Separate guidance statements are provided for VTE prevention in hospitalized patients with acute (moderate) illness and critically ill patients in the ICU. Each of the original questions and recommendations are divided into two questions: standard prophylaxis vs therapeutic (or escalated dose) prophylaxis and standard prophylaxis vs intermediate dose prophylaxis. As a result three additional recommendations are obtained based upon higher quality evidence.
CONCLUSION
Advances in care for patients with COVID-19 have improved overall outcomes. However, incidence of VTE in those patients remains elevated. It has been recommended to provide standard thromboprophylaxis for VTE in critically ill patients, and moderately ill patients with a low bleeding risk might benefit from therapeutic heparin.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts
2.
Chronic pain and poor sleep are troublesome bed partners.
3.
Saturated Fat Tied to Worse Survival After Prostate Cancer
4.
Guidelines for patient training and radiation protection for patients treated with radioactive iodine for thyroid cancer
5.
J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79
1.
Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer
2.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
3.
Exposure Modeling for Bispecific Antibodies: Scientific Foundations and Clinical Implications
4.
Risk Assessment of Treatment-Related Liver Injury in Cancer Care
5.
Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
How Advances in Cancer Research Are Improving Treatment Options
2.
Navigating the Complexities of Ph Negative ALL - Part III
3.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge